

SOUTHERN ARIZONA CLINICAL TRIALS

Bladder Cancer

PDLI for Met Bladder Cancer

USON 13227: A Phase II, Multicenter, Single-Arm Study of Mpdl3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer

Breast Cancer

Ist Line HER2 Neg Inoperable Breast

USON 11027: BKM 120 + Paclitaxel in patients w/ HER 2-locally adv or MBCA

Metastatic breast cancer-traditional therapy plus a novel PI3Kinase drug

Veliparib ABT-888 neoadj TNBC

USON 12152: A Randomized, Placebo-Controlled, Double-Blind, Phase III Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer

Niraparib vs PhyChoice HER2-gBRCA Breast

USON 13112: A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-Treated, Her2 Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Colon Cancer

MABpl for MCRC with Cachexia

USON 12177: Metastatic colon cancer, treatment with a novel antibody that prevents Cachexia

Lung Cancer

ABP215 vs Bevacizumab Adv NSCLC

USON 12064: A Randomized, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer

Aranesp in NSCLC

USON 08035: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy

Nivolumab v Invst's Choice NSCLC PD-LI+

USON 13168: An Open-Label, Randomized Phase III Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IIIB/IV or Recurrent Non-Small Cell Lung Cancer

Lymphomas

Relapsed/Refractory B-Cell/NHL (FL, LPL/WM, MZL), DLBCL, MCL

USON 12154: GS-9973 in relapsed or refractory hematologic malignancies

Relapsed lymphomas, treatment with a novel B-cell receptor agent

Ist Line Hodgkin's Lymphoma

USON 11282: Single agent brentuximab in adults age 60 and over

Hodgkin's disease, a novel antibody treatment for older patients

Ist Line Mantle Cell Lymphoma, Newly Diagnosed

USON 12225: Bruton's Tyrosine Kinase (BTK) inhibitor, PCI-32765 (Ibrutinib), in combination with Bendamustine and Rituximab versus BR alone

Mantle cell lymphoma, treatment with a new B-cell receptor agent

Ublitux + Ibrutinib in R/R CLL, SLL, MCL

USON 13152: A Multi-center Phase II Study with Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination with Ibrutinib in Patients with Select B-Cell Malignancies

Rev+Ritux, R/R FL, MZL, MCL

USON 13064: A Phase IIIB Randomized Study of Lenalidomide Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma

Multi Disease Site Studies Targeting Specific Biomarkers

PI3K Activated Tumors

USON 13020: PI3K inhibition with BKM120 in all patients with metastatic cancers harboring the PI3K mutation

Ovarian Cancer

Maint Niraparib PlatSensOvarian

USON 13008: A Phase III Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

Prostate Cancer

XL184 +Abiraterone w Bone Mets in cRPC

USON 13118: A Randomized Phase II Study of Cabozantinib in Combination with Abiraterone in Chemotherapy Naive Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer

For more information or to refer a patient, call 855-880-CURE.

